Table 3: COMORBIDITIES, N (%).

Comorbidity

Overall Sample

1 ED visits After WaaP

2 ED Visits After WaaP

P*

Hypertension

Yes

No

 

176 (47.2)

197 (52.8)

 

153 (47.4)

170 (52.6)

 

23 (46.0)

27 (54.0)

< 0.001

Obesity

Yes

No

 

166 (44.5)

207 (55.5)

 

145 (44.9)

178 (55.1)

 

21 (42.0)

29 (58.0)

< 0.001

Tobacco Use

Yes

No

 

144 (38.6)

229 (61.4)

 

114 (35.3)

209 (64.7)

 

30 (60.0)

20 (40.0)

< 0.001

Rhinitis

Yes

No

 

112 (30.0)

261 (70.0)

 

101 (31.3)

222 (68.7)

 

11 (22.0)

39 (78.0)

< 0.001

GERD

Yes

No

 

72 (19.3)

301 (80.7)

 

65 (20.1)

258 (79.9)

 

7 (14.0)

43 (86.0)

< 0.001

Diabetes

Yes

no

 

66 (17.7)

307 (82.3)

 

59 (18.3)

264 (81.7)

 

7 (14.0)

43 (86.0)

< 0.001

Atopy

Yes

No

 

36 (9.7)

337 (90.3)

 

30 (9.3)

293 (90.7)

 

6 (12.0)

44 (88.0)

< 0.001

Illicit Drug Use

Yes

No

 

35 (9.4)

338 (90.6)

 

27 (8.4)

296 (91.6)

 

8 (16.0)

42 (84.0)

< 0.001

COPD

Yes

No

 

42 (11.3)

331 (88.7)

 

32 (9.9)

291 (90.1)

 

10 (20.0)

40 (80.0)

0.02

 

 

 

 

 

Depression

Yes

No

 

14 (3.8)

359 (96.2)

 

13 (4.0)

310 (96.0)

 

1 (2.0)

49 (98.0)

0.049

OSA

Yes

No

 

13 (3.5)

360 (96.5)

 

11 (3.4)

312 (96.6)

 

2 (4.0)

48 (96.0)

0.010

Alcohol Use

Yes

No

 

27 (7.2)

346 (92.8)

 

22 (6.8)

301 (93.2)

 

5 (10.0)

45 (90.0)

0.60

CHF1

Yes

No

 

18 (4.8)

355 (95.2)

 

16 (5.0)

307 (95.0)

 

2 (4.0)

48 (96.0)

0.499

This table illustrates the comorbidities that exist in our patient population and their relationship with DECREASE in ED use.

*p-values were calculated using Pearson chi-square to indicate statistical significance of the relation of the acomorbidity to decreased ED visits